Analysts Set Expectations for ImmunityBio FY2026 Earnings

ImmunityBio, Inc. (NASDAQ:IBRX) – Analysts at HC Wainwright cut their FY2026 EPS estimates for ImmunityBio in a note issued to investors on Wednesday, August 6th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($0.29) for the year, down from their previous forecast of ($0.26). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for ImmunityBio’s current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for ImmunityBio’s FY2027 earnings at ($0.10) EPS and FY2028 earnings at $0.11 EPS.

ImmunityBio (NASDAQ:IBRX) last released its earnings results on Tuesday, August 5th. The company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). The firm had revenue of $26.43 million during the quarter, compared to analysts’ expectations of $21.95 million.

Other research analysts also recently issued reports about the stock. D. Boral Capital reissued a “buy” rating and issued a $30.00 target price on shares of ImmunityBio in a research report on Tuesday, August 5th. Piper Sandler raised shares of ImmunityBio from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $4.25 to $5.00 in a research report on Tuesday, May 20th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $12.25.

ImmunityBio Price Performance

ImmunityBio stock opened at $2.44 on Friday. The firm’s 50 day simple moving average is $2.78 and its 200-day simple moving average is $2.83. The company has a market cap of $2.31 billion, a P/E ratio of -5.08 and a beta of 0.12. ImmunityBio has a fifty-two week low of $1.83 and a fifty-two week high of $7.48.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Slow Capital Inc. purchased a new position in ImmunityBio during the first quarter valued at approximately $30,000. Financial Enhancement Group LLC purchased a new position in ImmunityBio during the second quarter valued at approximately $28,000. Compound Planning Inc. purchased a new position in ImmunityBio during the first quarter valued at approximately $30,000. Thrive Wealth Management LLC purchased a new position in ImmunityBio during the first quarter valued at approximately $30,000. Finally, Summit X LLC bought a new stake in ImmunityBio in the second quarter worth approximately $28,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.